Products
- Anti-Obesity Compound Library
- GPCR/G Protein-Targeted Compounds
- Immunology/Inflammation-Targeted Compounds
- JAK/STAT-Targeted Compounds
- MAPK-Targeted Compounds
- Membrane Transporter/Ion Channel-Targeted Compounds
- Metabolism-Targeted Compounds
- NF-κB-Targeted Compounds
- Microbiology/Virology-Targeted Compounds
- Neuronal Signaling-Targeted Compounds
- PI3K/Akt/mTOR-Targeted Compounds
- Oxidation-reduction-Targeted Compounds
- Proteases/Proteasome-Targeted Compounds
- Stem Cells/Wnt-Targeted Compounds
- Tyrosine Kinase/Adaptors-Targeted Compounds
- Ubiquitin-Targeted Compounds
Online Inquiry
Lidocaine
Cat. No.:
OB0225LY-0129
Appearance:
Solid
Purity:
≥99%
Identity:
Confirmed by NMR and HPLC.
Size:
Add to basket
Product Overview
Description:
Lidocaine is a local anesthetic and antiarrhythmic that blocks nerve impulse conduction.
Synonym:
Lignocaine; Alphacaine; Xylocaine; 137-58-6; 2-(Diethylamino)-N-(2,6-dimethylphenyl)acetamide; 2-(Diethylamino)-2',6'-acetoxylidide; 2-Diethylamino-N-(2,6-dimethylphenyl)acetamide; Acetamide, 2-(diethylamino)-N-(2,6-dimethylphenyl)-
CAS No.:
137-58-6
Compound CID:
3676
Formula:
C14H22N2O
Formula Weight:
234.34
Specification
Relative Density:
1.026 g/cm3
Stability:
3 years in powder form.
Storage:
Storage at -20°C.
Applications:
Lidocaine can be used for pain management and arrhythmia research.
Library Information
Targets:
Ion channels; Histamine receptors; MAPK kinase pathway; Transcription factors
Receptors:
ERK; H1 receptor; MEK; NF-κB; Sodium channel
Pathways:
Apoptosis; GPCR/G protein; Immunology/Inflammation; Membrane transporter/Ion channel; MAPK; Neuronal signaling; NF-κB
Plate Number:
AOCL-2
Plate Location:
f2
Empty Location:
a1-h1; a12-h12
Container:
96-well plate
Formulation:
10 mM DMSO
DMSO Max Solubility:
50 mg/mL; 213.37 mM
Water Max Solubility:
21.34 mM
